|Videos|June 30, 2017

Strategies for Improving the Management of Antibiotic Allergies

Elizabeth Phillips, MD, FRCPC, FRACP, explains different strategies for improving antibiotic allergy management.

Elizabeth Phillips, MD, FRCPC, FRACP, Professor of Medicine, Pharmacology, and Pathology, Vanderbilt University Medical Center, explains different strategies for improving antibiotic allergy management.

Interview Transcript (slightly modified for readability)

“Antibiotic allergy management is something that, in general, infectious disease physicians, internists, physicians, and pharmacists, probably don’t get enough education [on]. So, education would be one of the key pillars that needs to be improved here, and education alone would probably have a huge impact in terms of improving antibiotic allergy management, and hence, antibiotic appropriateness. But, what is not known at this point is what the ideal combination of strategies would be.

One of the hurdles, and we did a survey about a year ago of infectious disease physicians and allergists, is not all practicing physicians and pharmacists have access to these testing procedures, or have access to subspecialty testing procedures. So, a very important question is: Can we use decision support, for instance, decision support built into the electronic health record, to help facilitate strategies to manage patients with antibiotic allergy and penicillin allergy that would then improve outcomes? And there is data from a couple of recent studies that have been done to look at this, one of which looked at a response of skin testing service, and the other of which looked at different mechanisms, including decision support, sequentially with antibiotic allergy testing with penicillin allergy testing.

I think the ‘take home’ from that, is that using decision support, even without going for the need for a subspecialty service to do testing, has a significant benefit in terms of improving antibiotic appropriateness. And, when I say ‘antibiotic appropriateness,’ that generally means less use of broader-spectrum antibiotics that are not the first-line for that indication, and more use of narrower-spectrum beta-lactam antibiotics.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.